Wright Medical’s back on track, eager to close BioMimetic buyout

Wright Medical Group logo

Orthopedic giant Wright Medical (NSDQ:WMGI) is back on track, CEO Robert Palmisano told an audience at the J.P. Morgan Healthcare conference in San Francisco yesterday.

Following a rough patch, which included a deferred prosecution agreement over allegations that the company engaged in illegal kickbacks for hip and knee devices, Wright is looking to turn things around.

"In 2012 we began executing a transformational plan with the core focus of accelerating growth and improving our overall performance," Palmisano said yesterday. "We set out some pretty aggressive targets that we think we have actually surpassed."

The company set new benchmarks for progress in reforming its sales force, increasing physician training and spurring growth in its foot & ankle business.

Palmisano reported that Wright had already managed to convert 80% of its foot & ankle sales force to direct sales, 50% more than before.

"As we go forward, we did not think that we would be able to target the growth opportunity that is out there in foot & ankle if we did not get more control over our distribution channel," Palmisano said. "This was a big bet and I think it’s working out extremely well, and we couldn’t be happier."

He added that Wright had trained 1,360 U.S. physicians in the 1st 3 quarters of 2012, beating its own benchmark of 1,200 for the full year. The company had trained just 600 U.S. physicians in 2011.

Palmisano further noted that Wright’s foot & ankle business saw 14% growth in the 3rd quarter of 2012, compared with just 7% in Q4 2011.

Looking forward to 2013, the company plans to push productivity in its foot & ankle sales, aiming to hit a $1-million-in-revenue-per-salesperson benchmark, according to Palmisano.

The orthopedic devices maker also hopes to capture new opportunities in its fledgling ortho reconstruction devices business, sustain a strong cash flow and finally close the books on a $390 million acquisition for regenerative medicine company BioMimetic Therapeutics (NSDQ:BMTI).

Wright in November 2012 began buying up BMTI shares, taking out a 36% stake in the company after having agreed to pay up to $390 million in cash, stock and milestone payments for BioMimetic.

The acquisition ties into Wright’s plan to position itself as 60% extremities and biologics and 40% ortho recon, Palmisano said.

The deal is expected to close in the 1st quarter of fiscal 2013, and BioMimetic’s Augment Bone Graft should have FDA approval before the end of the fiscal year, he added.

The FDA in the past hasn’t always been favorable to BioMimetic’s Augment, a drug/device combination that uses a recombinant human platelet-derived growth factor and a bioresorbable synthetic bone matrix to stimulate bone growth in foot & ankle procedures.

U.S. health regulators in May 2011 published a negative review of the Augment bone graft, saying studies showed that Augment was not as successful as grafts taken from patients’ own bones.

An FDA advisory panel shortly after voted to recommend approval for the Augment treatment. A PMA nod for the product would make it the 1st new recombinant protein product to hit the orthopedics market in nearly 10 years.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply